Our Take
A higher response rate that doesn't extend survival is a clinical dead end, not a stepping stone—and it exposes Elahere's real weakness: patient selection via biomarker, not mechanism.
Why it matters
Elahere was forecast to hit $2.6bn in sales by 2032, with platinum-sensitive expansion as a key driver. The MIROVA failure closes off that path and hands an opening to biomarker-agnostic rivals in a market Elahere has owned since 2023.
Do this week
Oncology product teams: stress-test your survival-vs-response-rate assumptions in your pipeline now, before Phase III reads, because response rates alone no longer carry label expansion in recurrent ovarian cancer.
The trial miss and what it shows
AbbVie's Elahere (mirvetuximab soravtansine-gynx), a folate receptor alpha-directed antibody-drug conjugate, is the only FRα-targeted ADC approved for platinum-resistant ovarian cancer. On 29 May–2 June at ASCO 2026, the company presented Phase II MIROVA trial results in platinum-sensitive recurrent ovarian cancer (PSOC), a patient population with unmet need despite initial responsiveness to platinum chemotherapy.
The trial randomised patients with FRα-high expression (≥75%) to receive Elahere plus carboplatin followed by Elahere monotherapy, or investigator's choice platinum-based chemotherapy followed by PARP inhibitor maintenance. Elahere produced a confirmed overall response rate (ORR) of 66.2% versus 32.8% with chemotherapy. But median progression-free survival (PFS) did not improve: 9.53 months for Elahere versus 9.79 months for the control arm (HR 1.0; p=0.996).
Safety was a secondary concern. Elahere showed higher toxicity than chemotherapy alone, including increased neuropathy and ocular events, narrowing any potential benefit margin.
The expansion window closes
In 2025, Elahere generated $690m in global annual sales (company-reported). Analyst consensus forecast $2.6bn by 2032, with near-term growth driven by US and EU adoption in platinum-resistant disease and anticipated label expansion into platinum-sensitive disease. The MIROVA miss eliminates that expansion path in the near term.
More broadly, MIROVA demonstrates a structural problem: Elahere's reliance on the Ventana FOLR1 companion diagnostic inherently restricts the addressable patient population. A higher response rate in a selected subgroup that does not translate to survival advantage does not overcome patient population limitations—it reinforces them. This creates an opening for biomarker-agnostic competitors.
Emerging ADCs from Daiichi Sankyo (raludotatug deruxtecan, Datroway), Gilead (Trodelvy), and Corcept's recently approved Lifyorli (relacorilant) can sidestep FRα selection. Lifyorli, in particular, resensitizes tumors to platinum, a mechanism orthogonal to Elahere's targeted delivery. None yet match Elahere's development pace in ovarian cancer, but the competitive landscape has shifted.
Elahere retains one meaningful advantage: Phase III overall survival data from the earlier MIRASOL trial in platinum-resistant disease. That remains a durable regulatory asset. However, with MIROVA closing off platinum-sensitive expansion, Elahere's growth now rests on combinations and earlier-line indications, not label breadth.
What this means for clinical development
MIROVA reinforces a hard lesson: response rate and survival PFS are not interchangeable endpoints in ovarian cancer. A 33-percentage-point ORR lift that fails to shift the survival curve signals either inadequate follow-on therapy benefit, patient heterogeneity within the biomarker-selected cohort, or mechanism mismatch with disease biology in that population. This distinction matters upstream, in trial design and endpoint selection.
For sponsors evaluating ADC combinations or biomarker-gated strategies, MIROVA is a case study in how biomarker restriction can become a development ceiling, not a floor. Elahere's FRα-high gate optimized tolerability but may have inadvertently selected a subpopulation less responsive to the specific payload or schedule. Broader patient selection (or biomarker-agnostic design) trades patient population size for mechanistic flexibility—a trade that MIROVA suggests is increasingly necessary in recurrent disease.